Articles tagged with Vaccine Development
The Butantan Institute and MSD will exchange proprietary process information and clinical trial data, accelerating vaccine development. The partnership aims to create a tetravalent vaccine effective against all four dengue virus serotypes.
Researchers at the University of Hawaii have developed a recombinant subunit vaccine that uses only a small part of the Zika virus to protect against infection. The vaccine has shown efficacy in both mice and monkeys, providing an important milestone in its development.
A joint US-African effort to test the Bharat Biotech typhoid conjugate vaccine (TCV) on 250 children aged 9-36 months in Burkina Faso. The study aims to evaluate the TCV's efficacy when co-administered with other routine vaccines, such as yellow fever and meningitis A vaccines.
Researchers at Princeton University have developed a comprehensive way to evaluate how immune responses of humanized mice measure up to actual humans. The study highlights an experimental paradigm to address the gap in understanding immune responses to human pathogens and potential vaccines.
Scientists developed a human tissue culture construct to test immune responses to vaccines, enabling rapid assessment of candidates and accelerating the development process. The platform replicates immune responses in different populations and age groups, allowing researchers to select human vaccine candidates before human trials.
A new study analyzed nearly 3,800 U.S. outbreaks from 2009 to 2016 and found that severe outcomes were more frequent in outbreaks caused by specific genotypes of norovirus, particularly GII.4. The research may guide efforts to develop vaccines effective against norovirus disease.
The project leverages the multiplexed VaxArray platform to deliver high-quality MR vaccines faster and at lower production costs. Measles and rubella vaccines can prevent these highly contagious diseases, which have had a significant impact globally.
Three experimental Ebola vaccines showed persistent immunity for at least two and a half years, driving new vaccine development against diseases like Lassa fever, Nipah virus disease, and MERS-CoV. The study's findings have implications far beyond the Ebola fight, providing insights that could expedite vaccine development.
Researchers have developed a new vaccine strategy that offers partial protection against the highly contagious infectious bronchitis virus. The recombinant virus vaccine approach has potential to be more cost-effective and respond to emerging new virus strains, but further research is needed to develop a more robust vaccine.
Researchers at U.S. Military HIV Research Program (MHRP) advance experimental heroin vaccine through Phase I/IIa clinical trials. The vaccine aims to block the euphoria and addictive effects of heroin by binding it in the blood, potentially giving people a window to overcome addiction.
A novel synthetic DNA vaccine offers complete protection from Zaire Ebolavirus infection, with strong immune responses detected one year after the last dose. The vaccine's efficacy and durability support its potential as a new tool for protection against Ebola virus.
A University of Guelph researcher has developed a novel three-in-one vaccine targeting E. coli, Shigella, and Campylobacter jejuni, providing immunity against all three pathogens in mice tests. The vaccine may save lives in developing countries where these pathogens kill over 100,000 children under age five annually.
InDevR's VaxArray Influenza Pandemic HA potency assay enables rapid assessment of vaccine potency, reducing bottlenecks in vaccine production and administration. The assay demonstrates high sensitivity, accuracy, precision, and detection of a large panel of influenza viruses with pandemic potential.
Researchers at Kansas State University's Biosecurity Research Institute are studying African swine fever to prevent a potential US outbreak. The virus has already spread throughout Asia and Eastern Europe, threatening the global swine industry.
Researchers at UTMB create DNA-based vaccine that cuts production costs and storage needs by up to 80%. The new platform has potential to serve as a universal platform for developing live-attenuated vaccines for many viral pathogens.
The University of Montana has been awarded a $10 million contract to develop a universal flu vaccine. The project aims to improve both seasonal and pandemic flu vaccines by utilizing a synthetic dual-TLR adjuvant combination system called TRAC-478.
Researchers have identified a key protein called RAB11FIP5 that regulates natural killer cell activity in people who produce protective HIV antibodies. This discovery could lead to the development of a vaccine that triggers these antibodies before HIV infection.
Researchers from the University of Cambridge are launching a new clinical trial for a trivalent vaccine targeting Ebola, Lassa, and Marburg viruses. The vaccine builds on nearly two decades of research and aims to predict future outbreaks by studying natural animal reservoirs.
Researchers from the University of Copenhagen have developed a new vaccine for hay fever that targets specific sugar molecules to improve vaccination efficacy. The vaccine has been tested on mice and in vitro tests, showing potential for increased effectiveness and reduced treatment time.
A new study has identified a key factor in how Enterotoxigenic E. coli (ETEC) causes disease, giving scientists hope for a preventive vaccine. The researchers discovered that ETEC can sense oxygen levels to control toxin production, leading to breakthroughs in understanding the bacteria's virulence.
Researchers discovered that non-circulating memory T cells offer optimal protection against Salmonella infection, leading to the development of more effective and safe vaccines. The study's findings have significant implications for addressing enteric fever and invasive non-typhoidal Salmonellosis in resource-poor communities.
Researchers at UTMB successfully adapted a Zika virus vaccine to target and kill glioblastoma, the deadliest form of brain tumor. The altered vaccine effectively destroyed cancerous brain cells in mice without harming healthy ones.
LumaCyte's Radiance instrument offers rapid analysis of viral vaccines, speeding up development and production. This label-free method provides real-time monitoring of viral infectivity, reducing the time required to obtain an answer from 72 hours to just 5-10 minutes.
A study analyzing 538 vaccine candidates found that only about 128 are likely to reach the market, with many critical products lacking. The researchers estimate it would cost $16.3 billion to move current candidates through the pipeline, highlighting the need for increased investment and innovative approaches.
Gonorrhea is a rapidly worsening public health threat with over 550,000 new cases reported in 2017 and global yearly incidence estimated at 106.1 million cases. Researchers warn that animal models, like mouse models, may not accurately reflect the infection's severity or human immune responses.
Researchers from Karolinska Institutet have discovered that a baby's immune system undergoes dramatic changes within the first few weeks of life, adapting to its new environment. This phenomenon was made possible by using advanced techniques of immune cell analysis.
The Phase 1 clinical trial will analyze the immune response and assess the safety of the experimental vaccine, which has shown promise in earlier tests in rhesus macaques. The trial is designed to enroll 28 healthy adults and will last up to one year.
Developing vaccines for human parasites has proven challenging, with key challenges including immune response issues and limited scalability. GW researchers have outlined five key lessons learned along the critical path to vaccine development, aimed at accelerating progress in eradicating these diseases of poverty.
The incidence of tickborne infections in the US has risen significantly over the past decade. Lyme disease, caused by the spirochete Borrelia burgdorferi, accounts for most reported cases, with over 30,000 annual cases in the US but an estimated 10 times that number.
Chiung-Yu Hung receives $1.9 million grant to develop a vaccine for fungal infections, particularly valley fever caused by Coccidioides fungus. The goal is to prevent illness and save lives by stopping the spread of the infection before it occurs.
Researchers at Shinshu University have developed proteins that can self-assemble into complex nanostructures, a breakthrough in biomolecular engineering and synthetic biology. The new protein complexes can be designed to produce various chain-like structures on demand, opening up possibilities for innovative applications in biotechnology.
A Phase 2 study published in the NEJM found that vaccination can reduce the rate of sustained TB infections, with a 45.4% vaccine efficacy against BCG revaccination. The trial also showed promise for an investigational subunit vaccine candidate, H4:IC31, which reduced sustained infections by 30.5%.
Researchers at Osaka University have discovered a new mechanism of attachment for ETEC bacteria, leading to the development of anti-adhesion agents that can prevent bacterial binding without destroying the bacteria. These agents offer a novel treatment approach that may serve as an alternative to antibiotics.
A collaborative development of a dengue vaccine candidate has been announced by Institut Pasteur, BioNet-Asia and In-Cell-Art. The project aims to develop a single injection containing diverse antigens that vary in key positions to induce immune responses with unprecedented breadth and potency.
Scientists from Institut Pasteur and partners have developed a cellular test to verify the safety of live vaccines like yellow fever vaccine. The 3D culture model, BBB-Minibrain, detects rare mutant particles with neuroinvasive properties, paving the way for reduced animal testing in quality control.
The VaxArray NA reagent kit provides a standardized method for assessing neuraminidase in influenza vaccines, enabling manufacturers to meet current regulatory requirements and prepare for future trends. This breakthrough tool is expected to serve as an important new asset in the push for a more broadly protective or 'universal' flu va...
Researchers have developed a novel technique using spider silk microparticles to deliver vaccines directly to immune cells, increasing T lymphocyte responses. This method shows promise in strengthening vaccine efficacy, especially for cancer and infectious diseases.
Researchers develop flexible vaccine platform for single-dose protection against a range of infectious diseases. The technology offers rapid, large-scale production and is suitable for repeated use.
A new study finds that diseases common in the developing world may cause lymphoid tissue fibrosis and impaired vaccine responses. Researchers found significant differences in lymphoid anatomy between Ugandans and US participants, with Ugandans showing evidence of inflammation and immune activation.
A new nanoparticle vaccine developed by MIT researchers can deliver multiple doses of the polio vaccine in just one injection, making it easier to immunize children in remote regions. The vaccine uses a biodegradable polymer that releases the vaccine in bursts at defined time points, providing long-lasting immunity.
Scientists have developed a new vaccine technology that induces strong immunity and improved disease symptoms in immunized animals. The platform has achieved proof-of-concepts in veterinary medical use, including treatments for insect-bite hypersensitivity in horses and atopic dermatitis in dogs.
A promising malaria vaccine candidate, TBV, has shown to completely prevent transmission of the Plasmodium parasite to mosquitoes in Cameroon. The $3.2 million grant will further develop processes for human trials and a clinical treatment.
Scientists at NIH highlight innovations that can expedite vaccine development, shortening the timeline from decades to months. These advancements enable the application of standardized manufacturing processes to multiple vaccines, creating a collective database on safety and accelerating preclinical development.
Researchers at the University of Maryland School of Medicine are conducting trials to test the safety and efficacy of an H7N9 influenza vaccine. The vaccine, developed by Sanofi Pasteur, will be evaluated in healthy volunteers and elderly adults, with different dosages and adjuvant combinations tested.
The National Institute of Allergy and Infectious Diseases (NIAID) has unveiled a strategic plan to develop a universal influenza vaccine. The plan focuses on three key areas: improving understanding of influenza transmission, characterizing protective immunity, and designing universal vaccines.
A Phase 3 clinical trial demonstrates the safety and efficacy of IMVAMUNE, a non-replicating smallpox vaccine. The study showed twofold higher neutralizing antibodies compared to ACAM2000, a statistically superior immune response.
Scientists from Brazil and Senegal discovered the gene responsible for the mild effects of West Nile lineage 8, which could be used to develop a vaccine against more virulent lineages. The researchers found that the substitution P122S induces mutations linked to low replication rates, making it an ideal candidate for a vaccine.
The World Health Organization has prequalified the India-made rotavirus vaccine ROTAVAC, which will be available for procurement by UN agencies and Gavi for use in low-resource countries. The vaccine is the result of a unique social innovation partnership between Indian and international researchers, public, and private sectors.
Research connects preterm birth to adult heart disease by showing that fetal infection and inflammation disrupt genes crucial for normal heart development. This study uses a preterm animal model to demonstrate how inflammation can lead to incomplete heart development, increasing the risk of abnormal heart rhythms and heart failure.
The World Health Organization has prequalified the Typbar-TCV typhoid conjugate vaccine, offering longer-lasting protection and allowing administration to children under two years old. This step is crucial in expanding access to this lifesaving vaccine and reducing the burden of typhoid in high-risk areas.
The Michelson Prizes aim to support young scientists developing groundbreaking approaches to defeat major global diseases. Two $150,000 prizes will be awarded in June 2018 to identify innovative projects beyond conventional approaches.
A high-dose live oral vaccine has been found to be more effective in rapidly protecting individuals from cholera than the standard two-dose killed vaccine approach. This breakthrough could lead to improved control of outbreaks and lower mortality rates, particularly in low-income countries.
A new Army-developed Zika vaccine has induced a robust immune response in healthy adults, with over 90% of volunteers developing an immune response against the virus. The vaccine, developed by Walter Reed Army Institute of Research, was tested in three phase 1 studies and showed promising results.
A gene-based Zika vaccine developed by NIH scientists has been found to be safe and immunogenic in healthy adults, with 60-89% of participants generating a neutralizing antibody response. The vaccine, which includes a small piece of DNA called a plasmid, triggers the body to mount an immune response when injected into muscle.
Researchers have developed an inactivated Zika purified virus (ZPIV) vaccine that induced an immune response in participants and was well-tolerated, according to Phase 1 clinical trial results.
The Human Vaccines Project has reported high-level outcomes from two concurrent clinical studies aimed at deciphering the components and mechanisms of human immunity. The findings may provide important new insights into human immunity, which will be leveraged to launch expanded studies in 2018.
Scientists at IAVI and TSRI published new findings on HIV-blocking antibodies, shedding light on their development and potential as a vaccine design. The research highlights the importance of understanding how neutralizing antibodies develop to create an optimal vaccine strategy.
Scientists developed an enterovirus vaccine that protects against virus-induced diabetes in a mouse model for Type 1 diabetes. The study suggests the potential role of enteroviruses in human Type 1 diabetes and offers a new preventative treatment option.
Researchers are developing a universal influenza vaccine that would protect against all strains of flu globally. Current vaccines have varying effectiveness, with some years seeing only 10% effectiveness.
Researchers have developed a novel reagent to detect rare B cells indicating successful vaccination in veterinary animals. The method will be widely applicable for demonstrating immunity to other veterinary pathogens.